EMR 62203
Latest Information Update: 21 Apr 2004
At a glance
- Originator Merck KGaA
- Class Erectile dysfunction therapies
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 25 Mar 2004 Discontinued - Phase-II for Erectile dysfunction in Europe (unspecified route)
- 21 May 2003 Phase-II clinical trials in Erectile dysfunction in Europe (unspecified route)